Biomerica reports positive InFoods IBS endpoint trial results; multiple key endpoints show statistical significance

BIOMERICA INC

Subject Global Assessment of Relief (SGA) endpoint achieved p=0.007 for all IBS subtypes at 8 weeks.
Global Improvement Scale (GIS) endpoint p=0.040 for all patient subtypes (baseline vs 8 weeks).
Abdominal Pain Intensity endpoint p=0.012 for IBS-Mixed & IBS-Constipation patients as a group.
Bloating endpoint p=0.022 for IBS-Mixed & IBS-Constipation patients as a group (baseline vs 8 weeks).
Company plans to meet with FDA to review results and finalize pivotal trial for FDA clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.